类风湿关节炎(RA)是一种慢性致残性疾病,发病机制尚未完全明确。白细胞介素(IL)17在其关节软骨及滑膜病变中发挥重要作用,并且与其他促炎因子相互作用促进RA的发生,因此IL-17对于RA患者病因研究、远期治疗、阻止病情发展及改善患者预后具有重要作用。临床上关于IL-17及其辅助性T细胞(Th)17靶向相关药物的研究已获得一定成果,并在临床试验中初步使用,但对于使用的安全性及较其他药物的有效性方面仍需进一步研究。
Rheumatoid arthritis(RA) is a chronic disabling disease, and the pathogenesis is still not completely clear. The interlenkin(IL) 17 plays an important role in the articular cartilage and synovial lesions, and interact with other proinflammatory factors to promote RA, therefore, it is important for the study of the etiology, long-term treatment of RA,prevention from the disesase development and improving the prognosis of the patients. Studies on IL-17 and helper T cell (Th) 17 cells targeted drugs have achieved certain results and have been preliminarily used in clinical trials, though the safety and effectiveness compared to other drugs still need further studies.